By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bridge Therapeutics 



Birmingham  Alabama    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics' goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory.

YEAR FOUNDED:

2016

LEADERSHIP:

CEO: Dr. Greg Sullivan


Key Statistics


Email:
Ownership: Private

Web Site: Bridge Therapeutics
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->